BAI1基因在肝癌抗血管生成中的作用

肝癌电子杂志 ›› 2022, Vol. 9 ›› Issue (1): 36-40.

BAI1基因在肝癌抗血管生成中的作用

朱青¹, 魏哲文², 王小兵^3,*, 蔡建强^2,*

1.首都医科大学附属北京友谊医院检验科,北京 100050;
2.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京 100021;
3.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院分子肿瘤学国家重点实验室,北京 100021

收稿日期:2021-11-12 出版日期:2022-03-31 发布日期:2022-10-28
通讯作者: ^*王小兵,E-mail：wangxb@cicams.ac.cn;蔡建强,E-mail：caijianqiang@cicams.ac.cn
作者简介:朱青临床医学检验技师, 首都医科大学附属北京友谊医院, 检验科
基金资助:
国家自然科学基金面上项目（81772490,82172988）; 深圳市 “医疗卫生三名工程” 项目（SZS M202011010）

Role of BAI1 gene in anti-angiogenesis of hepatic carcinoma

Zhu Qing¹, Wei Zhewen², Wang Xiaobing^3,*, Cai Jianqiang^2,*

1. Department of Clinical Laboratory Diagnostics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;
2. Department of Hepatobiliary Surgery, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China;
3. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China

Received:2021-11-12 Online:2022-03-31 Published:2022-10-28

摘要/Abstract

摘要： 目的: 探讨BAI1基因在肝癌抗血管生成中的作用。
方法: 利用CRISPR/Cas9技术构建BAI1基因敲除的PLC/PRF/5细胞系。采用Sanger测序和蛋白质印迹法验证BAI1基因敲除结果。通过CCK8法检测BAI1基因敲除对肝癌细胞增殖的影响。将PLC/PRF/5细胞系与血管内皮细胞（human umbilical vein endothelial cells,HUVEC）共培养,检测BAI1基因对细胞成管能力的影响。构建裸鼠皮下移植瘤模型,在体内研究BAI1基因对肝癌生长和肿瘤血管生成的影响。
结果: Sanger测序结果显示BAI1基因目的区域成功敲除,敲除后细胞系中BAI1蛋白表达缺失。BAI1基因敲除后PLC/PRF/5细胞增殖显著加快,与HUVEC共培养后细胞成管数量显著增多。BAI1基因过表达的Hep3B细胞在裸鼠体内生长速度减慢,肿瘤组织中CD31阳性表达降低。
结论: 利用CRISPR/Cas9基因编辑技术成功构建BAI1基因敲除的PLC/PRF/5细胞系。BAI1基因可以抑制肝癌细胞的增殖和血管生成。

关键词: BAI1基因, 抗血管生成, 肝癌

Abstract: Objective:To explore the role of BAI1 gene in anti-angiogenesis of hepatic carcinoma.
Method:The BAI1 gene knockout PLC/PRF/5 cell line was constructed using CRISPR/Cas9 technology, and the knockout results were verified by Sanger sequencing and Western blotting. The CCK8 method was used to detect the effect of BAI1 gene knockout on the proliferation of liver cancer cell lines. The PLC/PRF/5 cell line was co-cultured with human umbilical vein endothelial cells(HUVEC) to detect the effect of BAI1 gene expression on the ability of cell tube formation. Transplanted tumor model was used to study the effect of BAI1 gene expression on liver cancer growth and tumor angiogenesis in vivo.
Result:Sanger sequencing and Western blotting showed that BAI1 gene was successfully knocked out. The proliferation of PLC/PRF/5 cells was significantly accelerated and the number of tube was increased significantly with BAI1 gene deficiency. The tumor growth was inhibited in vivo with BAI1 gene overexpression, and the positive expression of CD31 was decreased.
Conclusion:The BAI1 gene knockout PLC/PRF/5 cell line was successfully constructed using CRISPR/Cas9 technology. BAI1 gene deficiency promote the proliferation of liver cancer cells and angiogenesis.

Key words: BAI1 gene, Anti-angiogenesis, Hepatic carcinoma

朱青, 魏哲文, 王小兵, 蔡建强. BAI1基因在肝癌抗血管生成中的作用[J]. 肝癌电子杂志, 2022, 9(1): 36-40.

Zhu Qing, Wei Zhewen, Wang Xiaobing, Cai Jianqiang. Role of BAI1 gene in anti-angiogenesis of hepatic carcinoma[J]. Electronic Journal of Liver Tumor, 2022, 9(1): 36-40.

参考文献

[1] TANG A, HALLOUCH O, CHERNYAK V, et al.Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis[J]. Abdom Radiol (NY), 2018, 43(1): 13-25.
[2] THRIFT A P, NATARAJAN Y, LIU Y, et al. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 2117-2125.e.3.
[3] RICH N E, YOPP A C, SINGAL A G.Medical Management of Hepatocellular Carcinoma[J]. J Oncol Pract, 2017, 13(6): 356-364.
[4] CHEN L T, MARTINELLI E, CHENG A L, et al.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31(3): 334-351.
[5] COURI T, PILLAI A.Goals and targets for personalized therapy for HCC[J]. Hepatol Int, 2019, 13(2): 125-137.
[6] MORSE M A, SUN W, KIM R, et al.The Role of Angiogenesis in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920.
[7] ZHU D, HUNTER S B, VERTINO P M, et al.Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1[J]. Cancer Res, 2011, 71(17): 5859-5870.
[8] XU L, DU H, ZHANG Q, et al.BAI1-associated protein 2-like 2 is a potential biomarker in lung cancer[J]. Oncol Rep, 2019, 41(2): 1304-1312.
[9] HAMANN J, AUST G, ARAC D, et al.International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors[J]. Pharmacol Rev, 2015, 67(2): 338-367.
[10] HATANAKA H, OSHIKA Y, ABE Y, et al.Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1)[J]. Int J Mol Med, 2000, 5(2): 181-183.
[11] CORK S M, VAN MEIR E G. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development[J]. J Mol Med (Berl), 2011, 89(8): 743-752.
[12] YI M, JIAO D, QIN S, et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J]. Mol Cancer, 2019, 18(1): 60.
[13] REN F, WU K, YANG Y, et al.Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1alpha Expression[J]. Front Pharmacol, 2020, 11: 460.
[14] LIU L, CHAI L, RAN J, et al.BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module[J]. Carcinogenesis, 2020, 41(12): 1724-1734.
[15] HOLST F, HOIVIK E A, GIBSON W J, et al.Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth[J]. Sci Rep, 2016, 6: 25521.
[16] ZHANG H, ZHU D, ZHANG Z, et al.EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway[J]. Oncogene, 2020, 39(5): 1041-1048.
[17] KAUR B, BRAT D J, DEVI N S, et al.Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor[J]. Oncogene, 2005, 24(22): 3632-3642.
[18] NAM D H, PARK K, SUH Y L, et al.Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance[J]. Oncol Rep, 2004, 11(4): 863-869.
[19] CORK S M, KAUR B, DEVI N S, et al.A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1[J]. Oncogene, 2012, 31(50): 5144-5152.
[20] TIAN D W, HU H L, SUN Y, et al.Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs[J]. Mol Med Rep, 2016, 14(2): 1553-1559.
[21] WEN Y, ZHOU X, LU M, et al.Bclaf1 promotes angiogenesis by regulating HIF-1alpha transcription in hepatocellular carcinoma[J]. Oncogene, 2019, 38(11): 1845-1859.
[22] HORWITZ E, STEIN I, ANDREOZZI M, et al.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment[J]. Cancer Discov, 2014, 4(6): 730-743.
[23] LEI T, LING X.IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation[J]. World J Gastroenterol, 2015, 21(35): 10137-10149.
[24] LUGANO R, RAMACHANDRAN M, DIMBERG A.Tumor angiogenesis: causes, consequences, challenges and opportunities[J]. Cell Mol Life Sci, 2020, 77(9): 1745-1770.
[25] LI H.Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(3): 217-233.
[26] HUANG A, YANG X R, CHUNG W Y, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1): 146.
[27] RIBATTI D, VACCA A, NICO B, et al.Angiogenesis and anti-angiogenesis in hepatocellular carcinoma[J]. Cancer Treat Rev, 2006, 32(6): 437-444.